DNER and cancer: Given that many cancers are addicted to CRC, a combination of CRC-disrupting agents such as BET inhibitors with either existing treatment modalities or novel antitumor compounds such as Yap/Tead inhibitors may provide much-needed strategies to improve the overall response rates and progression-free survival in cancer patients.